Title: Comparision of Clinical Trial Application Approval Process with different countries guidelines
Authors: Miss Snehal Somana Wandre, Mrs. Shashikala Wali, Dr M.S.Ganachari, Mrs. Geetanjali Salimath, Mr. Revana S. Devarinti, Dr Deepak Tumari, Mr. Maruti Patil
DOI: https://dx.doi.org/10.18535/jmscr/v6i2.116
Abstract
Background: Clinical trial is vital step in the development of new and safe medicine & in the improving medical treatment. Clinical trial explore how a treatment reacts in the human body and are designated to ensure a drug is treated and effective before by regulatory authority and made available for doctors. The clinical trial approval or submission is the dossier that includes all documentation pertaining to the conduct of clinical trial in [country] according to the regulation. The clinical trial application must undergo a review or evaluation before being granted authorisation to conduct the trial in [COUNTRY] by [NAME OF NATIONAL REGULATORY AUTHORITY]. Drug trial regulation systems differs among countries and at this stage full harmonisation of the processes among the different International Conference of Harmonization of technical requirements for registration of pharmaceutical product for human use (ICH) regions of the world.
Methods: In this study, a methodology based on research articles, research journals, countries legal website and scientific publications have provided a basis for detailed analysis of timelines for clinical trial review and approval of eight regulatory authorities. This research shows that the various timelines and requirements of clinical trial approval process. Clinical trial regulatory guidelines of India compared with European Union, Canada, China, US, UK and Kenya and Australia. Timelines of clinical trial approval process and its requirements in India were compared with other respective countries.
Results: This study specifies various regulatory guidelines and safety requirements for conduct and inspection of clinical trials. It is required to take grant permission from regulatory authority to conduct clinical trial. The regulatory environment in USFDA, Kenya and Canada becomes more stringent in terms of timelines of approval.
The information regard to clinical trial application approval (CTA) obtained from the official website of different countries; those were used to compare timelines and requirements of clinical trial approval process in India with EU, US, UK, China, Canada, Kenya and Australia. The flowcharts were prepared to compare timelines & requirements of safety reporting in India with respective countries. Total eight regulatory authorities were included in this study which shows the different timelines and requirements for clinical trial approval process.
Conclusions: The regulatory guidelines in the clinical trials vary between countries. And it is important to take permission from regulatory authority before conducting clinical trial. Under the regulation, sponsor will be required to apply for authorisation to conduct clinical trial. There is different timelines and requirements of clinical trial application approval process for each regulatory body. This study methodology has enabled comparisons to be made both within agencies and between different authorities and has identified differences in the timelines that applications spend indifferent stages of the review.
Keywords: Regulatory authorities, Clinical trial approval process, Timelines and requirements of CTA.
References
- European Commission Memo, Brussels, 2 April 2014.
- Guidelines for Review/Evaluation of Clinical Trials of Vaccines and Biologicals.
- Understanding clinical trial booklet. GPS public affairs. 2013.
- New Regulatory Rules for clinical Trials in United States and the European Union.
- De Angelis C, Drazen JM, Frizelle FA et.al.Clinical trial registration: a statement from the international committee of Medical Journal Editors. Circ Res 2005;96:600-1.
- International Ethical Guidelines for Biomedical Research Involving Human Subjects (3rd ed.). Geneva: CIOMS in collaboration with WHO. Retrieved 1 December 2014.
- ICH Harmonized Guidelines for Good Clinical Practice E6 (R2) current step 2 version dated 11 June 2015.
- Guideline for Industry. Clinical Safety Data Management: Definitions And Standards For Expedited Reporting.ICH E2A.
- Reporting Of Serious Adverse Events In Clinical Trials To The Human Research Ethics Committee At Cahs: In accordance with the requirements as established by the NHMRC.
- EU ICH E2F, European Medicines Agency 2010, Sep2010[EMA/CHMP/ICH/309348/2008 Committee for medicinal products for human use (CHMP)]
- World journal of pharmacy and pharmaceutical sciences, Volume 5, Issue 8, 627-635 Review Article ISSN 2278 – 4357
- Registration requirement for ethics committees. Central Drugs Standard Control Organization website. New Delhi, India; Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Accessed on June 16, 2013.
- S. Department of Health & Human services, National Institute of Allergy and Infectious Diseases(NIAID)
- Therapeutic Goods Act 1989.
- U.S. Department of Health and Human Services. Food and Drug Administration Office of the Commissioner (OC).Center for Drug Evaluation and Research (CDER)Center for Biologics Evaluation and Research (CBER).Center for Devices and Radiological Health (CDRH)Office of Good Clinical Practice (OGCP) January 2009.